Pharmacoeconomic Analysis of Reported Use of ENTEREG(R) (alvimopan) Published in American Journal of Health-System Pharmacy
GSK $39.37 +0.36 +0.9% ADLR $1.57 -0.04 -2.5%
Released : Thursday, August 20, 2009 4:37 PM
GSK $39.37 +0.36 +0.9% ADLR $1.57 -0.04 -2.5%
Released : Thursday, August 20, 2009 4:37 PM
EXTON, PA and PHILADELPHIA, PA -- (MARKET WIRE) -- 08/20/09 -- Adolor Corporation (NASDAQ: ADLR) and GlaxoSmithKline (NYSE: GSK) today announced that an economic analysis of Phase 3 clinical trial data reported that the use of ENTEREG after bowel resection surgery decreased the amount of time patients spent in the hospital by one day, resulting in lower estimated hospital costs compared with placebo. The results, published in the American Journal of Health-System Pharmacy, were based on a post-hoc pharmacoeconomic analysis of pooled data consisting of 1,409 patients who participated in four randomized, double-blind, placebo-controlled, Phase 3 efficacy studies of ENTEREG conducted in North America.
ENTEREG is the first and only FDA-approved therapy indicated to accelerate the time to upper and lower gastrointestinal recovery following partial large or small bowel resection surgery with primary anastomosis, or reconnection of the intestine.
"The results from this analysis are positive for both bowel resection patients and healthcare providers," said Anthony J. Senagore, M.D., Vice President, Research and Education, Spectrum Health, Grand Rapids, MI, and one of the study authors. "The analysis of these Phase 3 North American studies concluded that using ENTEREG contributed to earlier discharge after surgery and, importantly, reduced overall estimated hospital costs."
News 
Market Data 
Discover 
AI
